Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration-Reference-Cited by-同舟云学术

Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration

Published:2017-06-07 Issue:12 Volume:60 Page:5057-5071
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Perry Matthew W. D.¹^ORCID,Björhall Karin¹,Bonn Britta¹,Carlsson Johan,Chen Yunhua²,Eriksson Anders¹,Fredlund Linda^ORCID,Hao Hai’e²,Holden Neil S.¹,Karabelas Kostas¹,Lindmark Helena,Liu Feifei²,Pemberton Nils¹,Petersen Jens,Rodrigo Blomqvist Sandra¹,Smith Reed W.¹,Svensson Tor¹,Terstiege Ina¹,Tyrchan Christian¹,Yang Wenzhen²,Zhao Shuchun²,Öster Linda

Affiliation:

1. Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden

2. Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00401

Reference33 articles.

1. PI3K and cancer: lessons, challenges and opportunities

2. Drugging PI3K in cancer: refining targets and therapeutic strategies

3. PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases

4. Targeting phosphoinositide 3-kinase δ for allergic asthma

5. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation;Journal of Medicinal Chemistry;2024-06-22

2. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities;Expert Opinion on Drug Discovery;2024-02-26

3. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization;Journal of Medicinal Chemistry;2023-09-22

4. Application of an “inhalation by design” approach to the identification and in-vitro evaluation of novel purine based PI3Kδ inhibitors;European Journal of Medicinal Chemistry;2023-06

5. Advances in the Discovery of Novel Inhaled PI3Kδ Inhibitors for the Treatment of Asthma;Current Medicinal Chemistry;2023-05